1
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, December 21, 2006: WO/2006/135627 (19 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R: Inhibitors of akt activity. Merck & Co, Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 22, 2006: WO/2006/065601 (17 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


3
Kevin Rodzinak
Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Banyu Pharmaceutical, Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing, Leff Matthew A, December 10, 2009: WO/2009/148916 (10 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


4
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


5
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Sanderson Philip E: Inhibitors of akt activity. Merck & Co, Layton Mark E, Rodzinak Kevin J, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, June 12, 2008: WO/2008/070134 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


6
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


7

8

9
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


10
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of akt activity. December 29, 2011: US20110319443-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...



Click the thumbnails below to visualize the patent trend.